Is 15% riser Synthomer plc a buy after beating expectations?

Should you pile into Synthomer plc (LON: SYNT) after today’s positive update?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Chemicals company Synthomer (LSE: SYNT) is one of today’s top risers after reporting strong results. Its performance during 2016 was ahead of expectations and shows that the company’s business model and strategy have been sound. Looking ahead, more growth is on the cards. But is it too late to buy the shares after today’s 15% price rise?

Improving performance

During the first three quarters of the year, Synthomer experienced positive trends in its European and North American divisions. They continued in Q4 and the company saw better than expected results across all business segments. It also benefitted from further improvements within its refreshed strategy, which has focused on new product initiatives, greater efficiency, a strengthened procurement function and greater investment in business development.

Strong performance was also recorded in Asia and the Rest of the World. Those regions performed modestly ahead of expectations in the final quarter, with the competitive dynamics in the Asian Nitrile business continuing to evolve. This follows the introduction of additional industry capacity in the second half.

Similarly, the integration and trading performance of Hexagon PAC has progressed in line with expectations and is on target to meet expectations for 2016. Taken together, the overall performance of the company is expected to have beaten previous guidance for 2016.

Further growth potential

Of course, the chemical industry isn’t a particularly consistent sector when it comes to profit growth. In the last five years, Synthomer has recorded falls in its bottom line in two of those years. It’s a similar story with sector peer Johnson Matthey (LSE: JMAT). Its bottom line has fluctuated significantly and this means it has lacked overall growth during the period.

But looking ahead, both stocks are expected to experience upbeat performance. In the case of Synthomer, its earnings are forecast to rise by 4% in 2017, followed by 7% growth in 2018. Alongside a price-to-earnings (P/E) ratio of 16.5, this indicates further share price growth could be on the horizon. However, its sector peer offers superior value for money as well as better growth potential. Johnson Matthey is expected to record a rise in its earnings of 7% in each of the next two financial years. With a P/E ratio of 14.4, this indicates that it offers greater upside than its industry peer.

Of course, Synthomer could prove to be a sound long-term buy. As today’s update showed it has improved its business model and is benefitting from better than expected performance in some of its key markets. This trend is expected to continue over the course of 2017, so it may yet beat its forecasts. However, since Johnson Matthey has a lower valuation, a wider margin of safety and superior growth prospects, it appears to be the more enticing buy of the two chemicals companies at the present time.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

A brilliantly reliable FTSE 100 share I plan to never sell!

This FTSE-quoted share has raised dividends for more than 30 years on the spin! Here's why I plan to hold…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

This 7.7% yielding FTSE 250 stock is up 24% in a year! Have I missed the boat?

When a stock surges, sometimes it can be too late to buy shares and capitalise. Is that the case with…

Read more »

Investing Articles

£13,200 invested in this defensive stock bags me £1K of passive income!

Building a passive income stream is possible and this Fool breaks down one investment in a single stock that could…

Read more »

Investing Articles

I think the Rolls-Royce dividend is coming back – but when?

The Rolls-Royce dividend disappeared in 2020 and has not come back. But with the company performance improving, might it reappear?

Read more »

British Pennies on a Pound Note
Investing Articles

Should I snap up this penny share in March?

Our writer is considering penny shares to buy for his portfolio next month. Does this mining company merit a place…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Stock market bubble – or start of a bull run?

Christopher Ruane considers whether the surging NVIDIA share price could be symptomatic of a wider stock market bubble forming.

Read more »

Investing Articles

Buying 8,254 Aviva shares in an empty ISA would give me a £1,370 income in year one

Harvey Jones is tempted to add Aviva shares to his Stocks and Shares ISA this year. Today’s 7.37% yield isn't…

Read more »

Investing Articles

Is the tide turning for bank shares?

Bank shares are trading on stubbornly cheap-looking valuations yet business performance in the sector is broadly robust. Should our writer…

Read more »